Key facts: Amgen Q3 beat; guidance raised; trials succeed; targets rise
Amgen (AMGN) reported Q3 revenue of $10.37B, up 8%, and adjusted EPS of $6.45, up 14%, beating forecasts. The company raised 2025 guidance. Positive Phase 3 results were reported for two drugs. Ten firms raised AMGN price targets, ranging from $410 to $536.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are fresh primary disclosures that can move the stock immediately.
Market read
Strong earnings and guidance raise make Amgen a near‑term buying candidate.
What to watch
Potential regulatory or reimbursement hurdles for the new trial data could temper upside.
Background
Amgen's Q3 earnings release includes trial data for TEZSPIRE, dazodalibep, and IMDELLTRA, plus analyst price‑target updates.
Ticker impact
Amgen reported Q3 revenue of $10.37 B (+8%) and adjusted EPS of $6.45 (+14%) beating forecasts, and raised 2025 revenue and EPS guidance.
potential upside as the market prices in the higher guidance
The beat and guidance lift improve earnings outlook, prompting buying pressure.
Market effects
Biotech sector may see broader optimism from Amgen's trial successes and guidance raise.
U.S. large‑cap biotech index could gain modestly.
Limited to investors tracking major pharma earnings.
Counterpoint
If guidance targets are overly optimistic, the stock could face a pull‑back after the initial rally.
Key entities
- companyAmgen
Biopharma company reporting Q3 results.
